Humana Inc. (NYSE: HUM) Investor Alert: Securities Fraud Case Moves Forward Following 22% Stock Drop; Schubert Jonckheer Investigating
π A U.S. District Judge ruled that a securities fraud lawsuit against Humana will move forward after finding defendants acted with intent to defraud.
βοΈ The lawsuit alleges Humana misled investors about rising post-pandemic patient care costs between July 2022 and October 2024.
πΈ Insiders sold over $104 million in Humana stock during the period of alleged misleading statements.
π Humana's stock price fell 22% after Star ratings declined and the truth about cost exposure was revealed in October 2024.
π Schubert Jonckheer & Kolbe is investigating potential wrongdoing by Humana's directors and officers regarding these allegations.
Risk Factors
- A U.S. District Judge found that Humana acted with intent to defraud investors by making false and misleading statements between July 2022 and October 2024.
- The company allegedly misled shareholders regarding its exposure to rising costs as patients returned for medical care after the pandemic.
- Insiders sold over $104 million in Humana stock during the period when the company allegedly misled investors about cost exposures.
- Humana's stock price dropped 22% following the revelation of misleading statements and sharp declines in Star ratings across its plans.
Full Analysis
A securities fraud lawsuit against Humana Inc. (NYSE: HUM) and its former leadership has moved forward following a ruling by U.S. District Judge Jennifer L. Hall, who found that defendants acted with intent to defraud investors between July 2022 and October 2024.
The core allegations state that Humana misled shareholders regarding the company's exposure to rising costs associated with patients returning for medical care after the pandemic. This alleged deception caused the stock to trade at artificially inflated prices before the truth emerged in October 2024, coinciding with sharp declines in Star ratings across many of Humana's plans.
Following the revelation of these issues, Humana's stock price dropped by 22%. During the alleged period of misleading statements, insiders sold over $104 million worth of company stock. The firm Schubert Jonckheer & Kolbe is currently investigating potential wrongdoing by Humana's directors and officers in connection with these specific allegations.
Current shareholders are being advised that they may have legal options regarding this case. The investigation focuses on the conduct of corporate officers and directors, specifically concerning the false and misleading statements made to investors during the specified timeframe.